Notable Runner: Today Sarepta Therapeutics Inc Stock Rises

Notable Runner: Today Sarepta Therapeutics Inc Stock Rises

The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) is a huge mover today! About 703,323 shares traded hands. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 82.38% since April 11, 2016 and is uptrending. It has outperformed by 76.24% the S&P500.
The move comes after 7 months positive chart setup for the $2.17 billion company. It was reported on Nov, 11 by Barchart.com. We have $64.84 PT which if reached, will make NASDAQ:SRPT worth $1.24B more.

Sarepta Therapeutics Inc (NASDAQ:SRPT) Ratings Coverage

Out of 21 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 12 rate it a “Buy”, 1 “Sell”, while 8 “Hold”. This means 57% are positive. Sarepta Therapeutics has been the topic of 52 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) earned “Overweight” rating by PiperJaffray on Monday, September 19. The stock has “Outperform” rating given by Oppenheimer on Wednesday, April 6. SunTrust downgraded the stock to “Reduce” rating in Tuesday, April 26 report. Roth Capital maintained the shares of SRPT in a report on Thursday, August 20 with “Buy” rating. The firm has “Buy” rating given on Wednesday, August 26 by William Blair. The rating was downgraded by Jefferies to “Underperform” on Friday, April 29. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Neutral” rating given on Tuesday, September 1 by SunTrust. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Outperform” rating given on Monday, September 19 by William Blair. Jefferies initiated the shares of SRPT in a report on Friday, October 23 with “Hold” rating. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) earned “Market Perform” rating by William Blair on Thursday, April 21.

According to Zacks Investment Research, “Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company’s diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.”

Insitutional Activity: The institutional sentiment increased to 1.16 in 2016 Q2. Its up 0.32, from 0.84 in 2016Q1. The ratio improved, as 31 funds sold all Sarepta Therapeutics Inc shares owned while 32 reduced positions. 31 funds bought stakes while 42 increased positions. They now own 33.70 million shares or 3.23% less from 34.83 million shares in 2016Q1.
Emerald Advisers Incorporated Pa has 0.22% invested in the company for 235,506 shares. International Grp Inc has invested 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). J Goldman & Lp accumulated 0.09% or 90,175 shares. Nationwide Fund Advsr has invested 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Invesco Limited holds 367,987 shares or 0% of its portfolio. Blackrock Institutional Trust Na holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 1.05 million shares. Alliancebernstein Ltd Partnership has 92,550 shares for 0% of their US portfolio. Susquehanna Grp Limited Liability Partnership has 549,962 shares for 0.01% of their US portfolio. The Ontario – Canada-based Manufacturers Life Ins Commerce The has invested 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Deutsche Savings Bank Ag accumulated 445,308 shares or 0.01% of the stock. California Employees Retirement Systems last reported 161,800 shares in the company. Qvt Finance Ltd Partnership holds 0.54% or 411,077 shares in its portfolio. Bnp Paribas Arbitrage Sa holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 1,655 shares. Moreover, Carl Domino has 0.23% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 13,000 shares. Jefferies Gru Limited Liability Corp holds 685,629 shares or 0.06% of its portfolio.

Insider Transactions: Since September 14, 2016, the stock had 0 insider purchases, and 8 selling transactions for $8.94 million net activity. Howton David T sold $465,200 worth of stock or 9,304 shares. $1.75M worth of shares were sold by Aphale Jayant on Monday, September 19. 7,311 Sarepta Therapeutics Inc (NASDAQ:SRPT) shares with value of $438,660 were sold by Ruff Shamim. On Wednesday, September 14 the insider Kaye Edward M. MD sold $736,710. On Monday, October 17 the insider Mahatme Sandesh sold $1.50M.

More important recent Sarepta Therapeutics Inc (NASDAQ:SRPT) news were published by: Profitconfidential.com which released: “Sarepta Therapeutics Inc: $40.00 Is Price Support on SRPT stock” on October 30, 2016, also Businesswire.com published article titled: “Sarepta Therapeutics to Present Company Overview at the Credit Suisse 25th …”, Forbes.com published: “Oversold Conditions For Sarepta Therapeutics (SRPT)” on November 02, 2016. More interesting news about Sarepta Therapeutics Inc (NASDAQ:SRPT) was released by: Benzinga.com and their article: “3 Reasons 2017 Launch Expectations For Sarepta’s EXONDYS 51 Are ‘Too High'” with publication date: November 11, 2016.

SRPT Company Profile

Sarepta Therapeutics, Inc., incorporated on June 5, 2013, is a biopharmaceutical company. The Firm is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Firm is engaged in the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Firm is primarily focused on advancing the development of its disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. The Firm is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment